September 2024's Top Undervalued Stock Selections For Savvy Investors

As global markets grapple with economic slowdown concerns and a notable dip in major indices, investors are increasingly seeking opportunities to capitalize on undervalued stocks. In this environment, identifying stocks that are trading below their intrinsic value can be particularly rewarding for those looking to navigate the current market volatility effectively.

Top 10 Undervalued Stocks Based On Cash Flows

Name	Current Price	Fair Value (Est)	Discount (Est)
Avant Group (TSE:3836)	¥2013.00	¥4008.96	49.8%
NSE (ENXTPA:ALNSE)	€29.30	€58.44	49.9%
Banca Sistema (BIT:BST)	€1.438	€2.88	50%
Progress Software (NasdaqGS:PRGS)	US$57.65	US$115.16	49.9%
HSS Engineers Berhad (KLSE:HSSEB)	MYR1.09	MYR2.17	49.8%
Feytech Holdings Berhad (KLSE:FEYTECH)	MYR0.895	MYR1.76	49.2%
Tortilla Mexican Grill (AIM:MEX)	£0.505	£1.01	49.9%
Vasta Platform (NasdaqGS:VSTA)	US$2.50	US$4.97	49.7%
Grifols (BME:GRF)	€9.306	€18.61	50%
Beijing Aosaikang Pharmaceutical (SZSE:002755)	CN¥10.93	CN¥21.79	49.8%

Click here to see the full list of 966 stocks from our Undervalued Stocks Based On Cash Flows screener.

Underneath we present a selection of stocks filtered out by our screen.

CVC Capital Partners (ENXTAM:CVC)

Overview: CVC Capital Partners plc is a private equity and venture capital firm specializing in various investment strategies including middle market secondaries, infrastructure, credit, management buyouts, leveraged buyouts, growth equity, mature investments, recapitalizations, strip sales and spinouts with a market cap of €20.24 billion.

Operations: CVC Capital Partners plc's revenue segments include middle market secondaries, infrastructure and credit, management buyouts, leveraged buyouts, growth equity, mature investments, recapitalizations, strip sales and spinouts.

Estimated Discount To Fair Value: 26.4%

CVC Capital Partners appears undervalued based on cash flows, trading at €19.04, which is 26.4% below its estimated fair value of €25.88. Despite a high level of debt, CVC's earnings are forecast to grow significantly at 26.1% per year over the next three years, outpacing the Dutch market's growth rate of 18.7%. Recent M&A activities, including bids for DB Schenker and Aavas Financiers, could further enhance its revenue prospects and overall valuation stability.

• Our expertly prepared growth report on CVC Capital Partners implies its future financial outlook may be stronger than recent results.
• Get an in-depth perspective on CVC Capital Partners' balance sheet by reading our health report here.

CLASSYS (KOSDAQ:A214150)

Overview: CLASSYS Inc. is a global provider of medical aesthetics devices with a market cap of ₩3.42 billion.

Operations: The company's revenue segment is primarily derived from Surgical & Medical Equipment, amounting to ₩204.37 million.

Estimated Discount To Fair Value: 17%

CLASSYS Inc. is trading at ₩53,400, approximately 17% below its estimated fair value of ₩64,330.38. The company's earnings are forecast to grow at 22.52% annually over the next three years, though this is slower than the broader Korean market's growth rate of 28.6%. Revenue is expected to increase by 19.3% per year, also outpacing the market average of 10.3%. Recent presentations at major financial conferences highlight ongoing investor interest and potential for future growth.

• According our earnings growth report, there's an indication that CLASSYS might be ready to expand.
• Click here and access our complete balance sheet health report to understand the dynamics of CLASSYS.

Shenzhen New Industries Biomedical Engineering (SZSE:300832)

Overview: Shenzhen New Industries Biomedical Engineering Co., Ltd. is a bio-medical company that focuses on the research, development, production, and sale of clinical laboratory instruments and in vitro diagnostic reagents to hospitals both in China and internationally, with a market cap of CN¥52.84 billion.

Operations: The company's revenue segments include CN¥4.28 billion from in vitro diagnostics.

Estimated Discount To Fair Value: 26.1%

Shenzhen New Industries Biomedical Engineering is trading at CN¥67.45, around 26.1% below its fair value estimate of CN¥91.29. The company's revenue and earnings are forecast to grow significantly at 22.8% and 23.24% per year, respectively, outpacing the Chinese market averages of 13.2% and 23.1%. Recent earnings for H1 2024 showed a solid performance with net income rising to CN¥903.15 million from CN¥750 million a year ago.

• Insights from our recent growth report point to a promising forecast for Shenzhen New Industries Biomedical Engineering's business outlook.
• Delve into the full analysis health report here for a deeper understanding of Shenzhen New Industries Biomedical Engineering.

Turning Ideas Into Actions

• Unlock our comprehensive list of 966 Undervalued Stocks Based On Cash Flows by clicking here.
• Have a stake in these businesses? Integrate your holdings into Simply Wall St's portfolio for notifications and detailed stock reports.
• Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.

Looking For Alternative Opportunities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com